Artificial intelligence (AI) based spatial assessment of tumor-infiltrating lymphocytes (TIL) and pathologic complete response in early HER2+ breast cancer (BC): Secondary analysis of NSABP B-41

551Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL assessment. Methods: Manual TIL assessment was completed per guidelines. Zero-shot, AI-powered pipeline (Case45) was used to analyze tumor microenviron...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 43; no. 16_suppl; p. 551
Main Authors Tang, Gong, AbdulJabbar, Khalid, Harris, Brent T., Rastogi, Priya, Freeman, Tanner, Maley, Sai Kumar, Yan, Haixi, Hook, Isaac, Wolmark, Norman, Salgado, Roberto, Swain, Sandra M.
Format Journal Article
LanguageEnglish
Published American Society of Clinical Oncology 01.06.2025
Online AccessGet full text
ISSN0732-183X
1527-7755
DOI10.1200/JCO.2025.43.16_suppl.551

Cover

Abstract 551Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL assessment. Methods: Manual TIL assessment was completed per guidelines. Zero-shot, AI-powered pipeline (Case45) was used to analyze tumor microenvironment (TME) from H&E slides, focusing on TILs and their spatial interplay with cancer cells. The algorithm identified all cells, deriving three metrics: pct_lymphocyte (lymphocytes/total cells), AI_TIL (adjacent-tumor lymphocyte to stromal cell ratio), hotspot_immune (normalized fraction of immune cell aggregates in relation to cancer/tissue). Spearman correlation coefficients evaluated correlations; logistic regression models assessed the relationship between TIL measurements and pCR, with and without gene expression adjustments. AUC assessed predictive performance, and univariate Cox models examined TILs' association with event-free survival (EFS). Results: Our analyses included tumors of 262 patients with early-stage HER2+ BC, 67% estrogen receptor (ER) positive, 51% positive lymph nodes. Poor histologic grade (p<0.001), non-luminal (p=0.006), and ER- tumors (p=0.003) were associated with higher manual TILs. Manual TILs were moderately associated with pct_lymphocyte (r= 0.34) and AI_TIL (r= 0.43). Perthe table, manual TILs were positively associated with pCR, the association was numerically stronger in ER- tumors (Interaction p=0.38). pct_lymphocyte and AI_TIL were positively associated with pCR, regardless of ER status. hotspot_immune was strongly associated with pCR (OR=1.26 for all, 1.29 in ER-, 1.22 in ER+, p=<0.001). TILs and ESR1 and ERBB2 provided complementary prognostic utility in pCR in trastuzumab-treated patients (AUC: 0.699-0.757). Among all subjects, there was no association between manual TILs and EFS (p=0.2); there was a marginal association between AI_TIL and EFS (p=0.06). Conclusions: The spatial characterization of TILs using an AI-powered tool shows promise as a prognostic biomarker in both HER2+/ER+ and HER2+/ER- BC, manual TIL assessment is prognostic in HER2+/ER- BC. The assessment of immune aggregates appears to be highly predictive of pCR. Further validation through prospective-retrospective studies, focused on the spatial immune heterogeneity in the TME, is required before integrating these biomarkers into routine clinical practice. Clinical trial information: NCT00486668. TILs measurements and pCR.Variable (continuous)CohortOR (95% CI)p-valueManual TILs %(10-unit inc.)All1.13 (1.04, 1.23)0.004ER-1.16 (1.02, 1.31)0.02ER+1.07 (0.95, 1.21)0.27Percentage of Lymphocyte (10-unit inc.)All2.00 (1.30, 3.07)0.002ER-1.75 (0.95, 3.21)0.07ER+1.93 (1.02, 3.62)0.04AI TILs(one-tenth inc.)All1.22 (1.06, 1.40)0.005ER-1.19 (0.98, 1.44)0.09ER+1.19 (0.97, 1.46)0.10
AbstractList 551 Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL assessment. Methods: Manual TIL assessment was completed per guidelines. Zero-shot, AI-powered pipeline (Case45) was used to analyze tumor microenvironment (TME) from H&E slides, focusing on TILs and their spatial interplay with cancer cells. The algorithm identified all cells, deriving three metrics: pct_lymphocyte (lymphocytes/total cells), AI_TIL (adjacent-tumor lymphocyte to stromal cell ratio), hotspot_immune (normalized fraction of immune cell aggregates in relation to cancer/tissue). Spearman correlation coefficients evaluated correlations; logistic regression models assessed the relationship between TIL measurements and pCR, with and without gene expression adjustments. AUC assessed predictive performance, and univariate Cox models examined TILs' association with event-free survival (EFS). Results: Our analyses included tumors of 262 patients with early-stage HER2+ BC, 67% estrogen receptor (ER) positive, 51% positive lymph nodes. Poor histologic grade (p<0.001), non-luminal (p=0.006), and ER- tumors (p=0.003) were associated with higher manual TILs. Manual TILs were moderately associated with pct_lymphocyte (r= 0.34) and AI_TIL (r= 0.43). Perthe table, manual TILs were positively associated with pCR, the association was numerically stronger in ER- tumors (Interaction p=0.38). pct_lymphocyte and AI_TIL were positively associated with pCR, regardless of ER status. hotspot_immune was strongly associated with pCR (OR=1.26 for all, 1.29 in ER-, 1.22 in ER+, p=<0.001). TILs and ESR1 and ERBB2 provided complementary prognostic utility in pCR in trastuzumab-treated patients (AUC: 0.699-0.757). Among all subjects, there was no association between manual TILs and EFS (p=0.2); there was a marginal association between AI_TIL and EFS (p=0.06). Conclusions: The spatial characterization of TILs using an AI-powered tool shows promise as a prognostic biomarker in both HER2+/ER+ and HER2+/ER- BC, manual TIL assessment is prognostic in HER2+/ER- BC. The assessment of immune aggregates appears to be highly predictive of pCR. Further validation through prospective-retrospective studies, focused on the spatial immune heterogeneity in the TME, is required before integrating these biomarkers into routine clinical practice. Clinical trial information: NCT00486668 . TILs measurements and pCR. Variable (continuous) Cohort OR (95% CI) p-value Manual TILs %(10-unit inc.) All 1.13 (1.04, 1.23) 0.004 ER- 1.16 (1.02, 1.31) 0.02 ER+ 1.07 (0.95, 1.21) 0.27 Percentage of Lymphocyte (10-unit inc.) All 2.00 (1.30, 3.07) 0.002 ER- 1.75 (0.95, 3.21) 0.07 ER+ 1.93 (1.02, 3.62) 0.04 AI TILs(one-tenth inc.) All 1.22 (1.06, 1.40) 0.005 ER- 1.19 (0.98, 1.44) 0.09 ER+ 1.19 (0.97, 1.46) 0.10
551Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL assessment. Methods: Manual TIL assessment was completed per guidelines. Zero-shot, AI-powered pipeline (Case45) was used to analyze tumor microenvironment (TME) from H&E slides, focusing on TILs and their spatial interplay with cancer cells. The algorithm identified all cells, deriving three metrics: pct_lymphocyte (lymphocytes/total cells), AI_TIL (adjacent-tumor lymphocyte to stromal cell ratio), hotspot_immune (normalized fraction of immune cell aggregates in relation to cancer/tissue). Spearman correlation coefficients evaluated correlations; logistic regression models assessed the relationship between TIL measurements and pCR, with and without gene expression adjustments. AUC assessed predictive performance, and univariate Cox models examined TILs' association with event-free survival (EFS). Results: Our analyses included tumors of 262 patients with early-stage HER2+ BC, 67% estrogen receptor (ER) positive, 51% positive lymph nodes. Poor histologic grade (p<0.001), non-luminal (p=0.006), and ER- tumors (p=0.003) were associated with higher manual TILs. Manual TILs were moderately associated with pct_lymphocyte (r= 0.34) and AI_TIL (r= 0.43). Perthe table, manual TILs were positively associated with pCR, the association was numerically stronger in ER- tumors (Interaction p=0.38). pct_lymphocyte and AI_TIL were positively associated with pCR, regardless of ER status. hotspot_immune was strongly associated with pCR (OR=1.26 for all, 1.29 in ER-, 1.22 in ER+, p=<0.001). TILs and ESR1 and ERBB2 provided complementary prognostic utility in pCR in trastuzumab-treated patients (AUC: 0.699-0.757). Among all subjects, there was no association between manual TILs and EFS (p=0.2); there was a marginal association between AI_TIL and EFS (p=0.06). Conclusions: The spatial characterization of TILs using an AI-powered tool shows promise as a prognostic biomarker in both HER2+/ER+ and HER2+/ER- BC, manual TIL assessment is prognostic in HER2+/ER- BC. The assessment of immune aggregates appears to be highly predictive of pCR. Further validation through prospective-retrospective studies, focused on the spatial immune heterogeneity in the TME, is required before integrating these biomarkers into routine clinical practice. Clinical trial information: NCT00486668. TILs measurements and pCR.Variable (continuous)CohortOR (95% CI)p-valueManual TILs %(10-unit inc.)All1.13 (1.04, 1.23)0.004ER-1.16 (1.02, 1.31)0.02ER+1.07 (0.95, 1.21)0.27Percentage of Lymphocyte (10-unit inc.)All2.00 (1.30, 3.07)0.002ER-1.75 (0.95, 3.21)0.07ER+1.93 (1.02, 3.62)0.04AI TILs(one-tenth inc.)All1.22 (1.06, 1.40)0.005ER-1.19 (0.98, 1.44)0.09ER+1.19 (0.97, 1.46)0.10
Author Swain, Sandra M.
AbdulJabbar, Khalid
Maley, Sai Kumar
Hook, Isaac
Harris, Brent T.
Wolmark, Norman
Salgado, Roberto
Rastogi, Priya
Yan, Haixi
Tang, Gong
Freeman, Tanner
Author_xml – sequence: 1
  givenname: Gong
  surname: Tang
  fullname: Tang, Gong
– sequence: 2
  givenname: Khalid
  surname: AbdulJabbar
  fullname: AbdulJabbar, Khalid
– sequence: 3
  givenname: Brent T.
  surname: Harris
  fullname: Harris, Brent T.
– sequence: 4
  givenname: Priya
  surname: Rastogi
  fullname: Rastogi, Priya
– sequence: 5
  givenname: Tanner
  surname: Freeman
  fullname: Freeman, Tanner
– sequence: 6
  givenname: Sai Kumar
  surname: Maley
  fullname: Maley, Sai Kumar
– sequence: 7
  givenname: Haixi
  surname: Yan
  fullname: Yan, Haixi
– sequence: 8
  givenname: Isaac
  surname: Hook
  fullname: Hook, Isaac
– sequence: 9
  givenname: Norman
  surname: Wolmark
  fullname: Wolmark, Norman
– sequence: 10
  givenname: Roberto
  surname: Salgado
  fullname: Salgado, Roberto
– sequence: 11
  givenname: Sandra M.
  surname: Swain
  fullname: Swain, Sandra M.
BookMark eNqFkc2O0zAQxyO0SHQX3mGOrVCCHcdJiri01cIWVSxiF4mb5TiT1uDYke1qldfjyXC1cOY0Gs38P6TfdXZlncUsA0oKWhLy7vPuvihJyYuKFbQW4TxNpuCcvsgWlJdN3jScX2UL0rAypy378Sq7DuEnIbRqGV9kvzc-6kErLQ1oG9EYfUSrEJab_Qo6GbCHMMl4ucsQMIQRbQQ3QDyPzufaDtpEnx7sEcw8Tien5ogBlo_7wwqk7SGpT864o1ag3DgZjAgew-RswJQJKL2Z4e72W_kWOo8yRFAyVfCw3O5W7-EBlbO99HNyk2YOOlzivzxstl9hm1f0dfZykCbgm7_zJvv-8fZxd5cf7j_td5tDrigpad5RVHWNKOv1upaNLOm64XXfVl1V9WlHztu6Z6RjXcU61ZOBDSXlXTWQjhPG2E3WPvsq70LwOIjJ6zH1EpSICwuRWIgLC1Ex8Y-FSCyS9MOz9MmZiD78Mucn9OKE0sTT_-V_AGhil4I
ContentType Journal Article
Copyright 2025 by American Society of Clinical Oncology
Copyright_xml – notice: 2025 by American Society of Clinical Oncology
DBID AAYXX
CITATION
DOI 10.1200/JCO.2025.43.16_suppl.551
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1527-7755
EndPage 551
ExternalDocumentID 10_1200_JCO_2025_43_16_suppl_551
486840
Genre meeting-report
GroupedDBID ---
.55
0R~
18M
34G
39C
4.4
5GY
5RE
8F7
AAQQT
AARDX
AAWTL
AAYEP
ABBLC
ABJNI
ABOCM
ACGFO
ACGFS
ACGUR
ADBBV
AEGXH
AENEX
AIAGR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BYPQX
C45
CS3
DIK
EBS
EJD
F5P
F9R
FBNNL
FD8
GX1
HZ~
IH2
IPNFZ
K-O
KQ8
L7B
LSO
MJL
N9A
O9-
OK1
OVD
OWW
P2P
QTD
R1G
RHI
RIG
RLZ
RUC
SJN
TEORI
TR2
TWZ
UDS
VVN
WH7
X7M
YFH
YQY
.GJ
08G
08P
29K
2WC
3O-
53G
5VS
8WZ
A6W
AAKAS
AAQOH
AAYOK
AAYXX
ADZCM
AFFNX
AI.
ASPBG
AVWKF
AZFZN
CITATION
D-I
EX3
FEDTE
H13
HVGLF
J5H
N4W
NTWIH
UHU
VH1
WOQ
WOW
ZGI
ID FETCH-LOGICAL-c1021-b1ec66eea6996a7a219756d84b44da7ae5586d30b3b43bcd0f3f215b4f0b50333
ISSN 0732-183X
IngestDate Thu Jul 03 08:43:28 EDT 2025
Mon Jun 09 20:30:16 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 16_suppl
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1021-b1ec66eea6996a7a219756d84b44da7ae5586d30b3b43bcd0f3f215b4f0b50333
Notes Abstract Disclosures
PageCount 128
ParticipantIDs crossref_primary_10_1200_JCO_2025_43_16_suppl_551
wolterskluwer_health_10_1200_JCO_2025_43_16_suppl_551
PublicationCentury 2000
PublicationDate 20250601
2025-06-00
PublicationDateYYYYMMDD 2025-06-01
PublicationDate_xml – month: 6
  year: 2025
  text: 20250601
  day: 1
PublicationDecade 2020
PublicationTitle Journal of clinical oncology
PublicationTitleAbbrev ASCO MEETING ABSTRACTS
PublicationYear 2025
Publisher American Society of Clinical Oncology
Publisher_xml – name: American Society of Clinical Oncology
SSID ssj0014835
Score 2.4790862
Snippet 551Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL...
551 Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL...
SourceID crossref
wolterskluwer
SourceType Index Database
Publisher
StartPage 551
Title Artificial intelligence (AI) based spatial assessment of tumor-infiltrating lymphocytes (TIL) and pathologic complete response in early HER2+ breast cancer (BC): Secondary analysis of NSABP B-41
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&DO=10.1200/JCO.2025.43.16_suppl.551
Volume 43
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLW2ISEkhGCAGF-6DzBt6lLaOF-Dp7ZsrNtoC-ukvkWO44yJ0qC0FSo_j1_GvXbSpNoQsJeoSRXb0fWx77XPPWbslS8bMuaesOzY8SzH58IioSLLbyil-L4nVazZFj3v6Nw5HrmjtfV3FdbSfBbV5c9r80puYlV8hnalLNn_sOyyUHyAv9G-eEUL4_WfbNzKNNNHn7tRldZEr7HVpXif5qi4NiXWNGkCLFU4NTNg_i3NLGzG5VhL504uauMF2jaVi3wtdtg9pUK0lICY5cOkIaGjq13LDL3WqI5oneSjg8_2a7tdi4jpPiNCmSSlCjtod7AgWnw4o_g7JqaeqKih9M5a7UGtbRlxqmt85WX-ZjqRK_sAw3y5-0Oaz8B6Jyuej49FFBnu-MkXDDXicqTNMiOr0Na6VMN6udOFfvCFJjcMssuFqK6H2G7J26qkINDYmLNeidVSNLJfbaQZZH1uWzisjcx8mE8Cto9Rh5EPLmYJIyZVoMELp3ToamXkd3PdXFW9uzI_2ebo7U6_Tk2vO7xeFFVfFlCVBO_1w8H7w_C02ztZ_VN7IE5AUj3r7Jbt-5qjcPKp3EJzAnO6bPGBOY0NW_DmT_Wv-GZ3f6TE15h-1ekaFadreJ_dy3sAtEzXf8DW1GST3f6Y80E22fbAKK8v9mBYJhJO92AbBqUm--Ih-1VCBapQgZ1Wdxc0TCCHCZQwgTSBqzCBCkxgB0GyCwgRKCECBUSggAjWCRoiQBCpgQEIGIDATruz-xaW0IACGlS9hgYQNB6x88ODYefIyo8vsWSTiE9RU0nPU0p4-_ue8AX6Br7rxYETOU6M98p1Ay_mjYhHDo9k3Eh4gg545CSNiMgF_DHbmKQT9YRBIrhMhBc0SJtJ8kC4scJ4U_Ik4VL4_hZrFoYLvxuVmpCie5u2qjv9kIwdOjwsjB2isbeYu2Lh0CRe__W9pzd87xm7U8L1OduYZXP1Ah36WfRSd9zf-k76Cw
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Artificial+intelligence+%28AI%29+based+spatial+assessment+of+tumor-infiltrating+lymphocytes+%28TIL%29+and+pathologic+complete+response+in+early+HER2%2B+breast+cancer+%28BC%29%3A+Secondary+analysis+of+NSABP+B-41&rft.jtitle=Journal+of+clinical+oncology&rft.au=Tang%2C+Gong&rft.au=AbdulJabbar%2C+Khalid&rft.au=Harris%2C+Brent+T.&rft.au=Rastogi%2C+Priya&rft.date=2025-06-01&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=43&rft.issue=16_suppl&rft.spage=551&rft.epage=551&rft_id=info:doi/10.1200%2FJCO.2025.43.16_suppl.551&rft.externalDBID=NO_PDF_LINK&rft.externalDocID=486840
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon